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Abstract
There are currently still limitations in the diagnosis of tuberculosis (TB). Sputum collection as specimen for 
diagnosis is not only difficult but also has low sensitivity.In blood, IP-10/CXCL-10 chemokine plays a role in 
inducing the movements of chemotactic inflammatory cells towards the sites of inflammation. A high level of 
IP-10 is found in active pulmonary TB patients and significantly decline after the patients have completed the TB 
treatments. The aim of this study was to analyze the decline of the IP-10 level before and after 2 months of TB 
treatment. This study was conducted from March to Juni 2020. This was a comparative observational cohort study 
on active pulmonary TB patients who were >18 years old at the DOTS Clinic of Dr. Hasan Sadikin General Hospital 
Bandung. Thirty patients who met the inclusion criteria were followed up until 2 months of TB treatment. Serum 
of  these patients were collected and examined for the IP-10 level before and after 2 months of TB treatment. It 
was demonstrated that the median IP-10 level in new active pulmonary TB patients was 384.1 pg/mL (136.70–
779.80) and dropped to 251.85 pg/mL (91.10–698.30) (p<0.001) two months of TB treatment. Thus, the IP-10 
level in the active pulmonary TB patients is significantly declined (p<0.001) after 2 months of TB treatment and 
that serum IP-10 level could be considered as a non-sputum-based marker to monitor TB treatment.
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IP-10 sebagai Biomarker Non-Sputum pada Monitoring 
Pengobatan Tuberkulosis
Abstrak
Diagnosis tuberkulosis (TB) saat ini masih mengalami kendala. Pemeriksaan spesimen sputum selain 
pengambilannya sulit juga sensitivitasnya rendah, baik mikroskopik maupun kultur. Kemokin IP-10/CXCL-10 
merupakan kemokin pro-inflamasi yang berperan menginduksi pergerakan sel inflamasi menuju lokasi inflamasi. 
Pada penderita TB paru aktif ditemukan kadar dalam serum tinggi dan menurun signifikan setelah penderita 
menyelesaikan pengobatan. Tujuan penelitian ini adalah menganalisis penurunan kadar IP-10 serum pada 
penderita TB paru aktif baru dibanding dengan 2 bulan pascapengobatan TB. Penelitian ini bersifat observasional 
komparatif dengan rancangan penelitian kohort. Subjek penelitian adalah penderita TB paru aktif baru berumur 
>18 tahun yang berobat ke Poliklinik DOTS Rumah Sakit Dr. Hasan Sadikin Bandung yang diikuti sampai 2 
bulan pengobatan. Serum subjek sebelum dan setelah pengobatan 2 bulan dikumpulkan serta disimpan pada 
suhu -80⁰C sampai pemeriksaan kadar IP-10. Penelitian ini dilakukan sejak Maret sampai Juni 2020. Terdapat 
30 subjek yang memenuhi kriteria inklusi. Median kadar IP-10 pada penderita TB paru aktif baru adalah 384,1 
pg/mL (136,70–779,80), menurun bermakna setelah pengobatan 2 bulan, yaitu 251,85 pg/mL (91,10–698,30) 
(p<0,001). Simpulan, penelitian ini menunjukkan kadar IP-10 dapat digunakan sebagai penanda berbasis non-
sputum untuk monitoring pengobatan TB.
Kata kunci: IP-10, monitoring pengobatan tuberkulosis, tuberkulosis
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Introduction
Tuberculosis (TB) is one of the top 10 causes 
of death worldwide and Indonesia has the 
second highest incidence in the world, after 
India.1 Currently, there are still limitations in 
the diagnosis of TB. Specimen collection from 
sputum is not only difficult but also produce a 
low sensitivity in both microscopic and culture 
examination. In addition, Xpert MTB/RIF assay 
requires laboratory facilities and experts.2 
Evaluation of TB treatment still relies on 
sputum conversion after the first 2 months of TB 
treatment, which actually cannot be fully used 
as an indicator of the success of treatment.3,4 
Since 2015, World Health Organization (WHO) 
has been encouraging scientists towards the 
discovery of new non-sputum-based diagnostic 
methods from the individual host’s responses, 
aiming to increase the sensitivity and specificity 
of pulmonary TB diagnosis as well as assisting 
in TB treatment evaluation.5 Currently, the host 
response is a concern for studies as available 
host response tests such as Interferon-γ (IFN-γ) 
or known as the interferon gamma release assay 
(IGRA) cannot be used to differentiate between 
active TB and latent TB as well as  for monitoring 
TB treatment result.6-8
There are other cytokines and chemokines that 
have been studied as alternative markers of host 
response to Mycobacterium tuberculosis (MTB) 
infection, such as C-X-C motif chemokine ligand 
10 (CXCL10) or interferon-γ inducible protein 
10 (IP-10). The IP-10 is a pro-inflammatory 
chemokine which is stimulated by IFN-γ in the 
site of  inflammation as the response to MTB 
infection. This chemokine  plays a role in inducing 
the movements of chemotactic inflammatory 
cells towards the sites of inflammation.9-11 IP-10 
is produced mainly by the  antigen presenting 
cell (APC) and the level is 100-fold higher than 
IFN-γ after MTB infection.6,7,11 A high level of IP-
10 iss found in active pulmonary TB patients 
and decreases significantly after the completion 
of the anti-TB treatments.12 This study aimed to 
analyze the decrease of the IP-10 level before 
and after 2 months of TB treatment.
Methods
This was a comparative observational cohort 
study as a part of  “Using host-responses and 
pathogen genomics to improve diagnostics 
for tuberculosis in Indonesia” research in 
collaboration with the London School of Hygiene 
and Tropical Medicine. Subjects were active 
pulmonary TB patients aged >18 years old who 
were treated at the DOTS clinic of Dr. Hasan 
Sadikin General Hospital Bandung, Indonesia. 
Subjects were diagnosed by clinicians based 
on the International Standard of Tuberculosis 
Care (ISTC) and followed for 2 months.13 Only 
subjects with total compliance were included  in 
this  study. The total compliance was defined as 
patients who perform visits and take medication 
according to the doctor’s instructions, while non-
compliance was defined as patients who stop 
taking TB treatment or not taking TB treatment 
properly.14
The exclusion criteria in this study 
were patients with extrapulmonary TB, 
malignancy and/or undergoing chemotherapy, 
diabetes mellitus, hepatitis B and C, human 
immunodeficiency virus (HIV), pulmonary 
infection other than TB, and having steroid or 
immunomodulatory therapy for more than 2 
weeks. The exclusion criteria were based on 
patient’s history, physical examination, chest 
X-ray and laboratory results {fasting blood 
glucose and 2 hours post prandial test, anti-HIV 
test, hepatitis B surface antigen test (HBsAg), 
and hepatitis C antibody test (anti-HCV)}.This 
study was conducted from March to June 2020. 
Patients were instructed to provide sputum 
samples on the day of first attendance before 
TB treatment initiation. Samples were then 
examined using smear, culture, and GeneXpert 
method to confirm TB diagnosis.13 Three mL 
of blood were collected at D0 and D60 using 
plain vacutainer tubes and transported to the 
Central Laboratory of the Clinical Pathology 
Department, Dr. Hasan Sadikin General Hospital 
Bandung, Indonesia, and were centrifuged at 
3000 g for 15 minutes. Serum were then stored 
at −80 °C for a maximum of 3 months before the 
IP-10 testing was performed. The measurement 
of the IP-10 levels used was the sandwich 
enzyme-linked immunosorbent assay (ELISA) 
method.15 Data were then analyzed for normality 
using the Saphiro-Wilk test and the difference 
was assessed using the Wilcoxon Signed Ranks 
Test using the Statistical Package for the Social 
Science (SPSS) software version 24.0 for 
Windows. This study applied 95% confidence 
level (α=0.05) with a p value of <0.05 deemed 
to be statistically significant difference. Ethical 
approval for this study was obtained from the 
Health Research Ethics Committee of Dr. Hasan 
Sadikin General Hospital Bandung, Indonesia, 
through the issuance of the ethical clearance No. 
LB.02.01/X.6.5/61/2020.
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Table 2 Differences of Serum IP-10 Levels in New Active Pulmonary TB Patients and After 2 
 Months of TB Treatment


















Age (year)*  37±12
GeneXpert examination  
Sensitive 5
Resistant 25
Smear examination  
Negative 11
Scanty 5 
Positive 1 9 
Positive 2 2 
Positive 3 3
Culture examination  
Positive 26 
Negative 4 





Leukocyte count (/mm3)*  8.396±2.216
Total neutrophils (103/uL)*  5.74±2.06
Total lymphocytes (103/uL)* 1.72±0.71
Total monocytes (103/uL)^ 0.6 (0.22–1.42)
Total eosinophils (103/uL)^ 0.08 (0.01–0.49)
* =Mean ± Standard deviation; ^  =Median (Range); The examination was performed before TB treatment
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Results
Between March and June 2020, 30 subjects were 
enrolled with male subjects outnumbered the 
female subjects. The mean age of the subject were 
37±12 years old. During this study, most subjects 
suffered from MDR-TB. Nevertheless, the levels 
of IP-10 were not statistically difference between 
sensitive and MDR-TB subjects. A similar 
condition was also found in the positivity of 
smear examination. Leukocytes as the producer 
of IP-10 were found to be within normal limits. 
No analysis was performed to elaborate the 
relation between the type of leukocytes and 
the IP-10 level. The characteristics of subjects 
enrolled in the study are listed in Table 1.
The median IP-10 levels before and after two 
months of TB treatment demonstrated that the 
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IP-10 level median decreased significantly from 
384.1 pg/mL to 251.85 pg/mL (p<0.001) after 2 
months of TB treatment as presented in Table 2.
Discussion
Sputum smear and culture conversion at 2 
months has long been used as the predictor of 
a successful TB treatment; however, sputum 
samples at 2 months of TB treatment are difficult 
to obtain in patients who respond to therapy. 
Subsequently, other biomarkers for monitoring 
TB treatment are needed.
IP-10 is a pro-inflammatory chemokine that 
is secreted by macrophages and dendritic cells in 
the lung organs as a response to MTB Infection. 
The IP-10 induces the Th1 cells to return to the 
lung organs and produce interferon gamma, 
TNF-α, and IL-2. Interferon gamma (IFN-γ) is a 
more dominant cytokine that stimulates the APC 
to produce IP-10, when compared to TNF-α and 
IL-2, at the site of MTB infection. A high level of 
IP-10 is found after TB exposure or reactivation 
of a latent infection and then a decrease is 
observed after 2 months of TB treatment due 
to the reduced number of activated MTB and 
IFN-γ response to T cells.6,10,11 Those properties 
have made IP-10 a promising candidate for the 
surrogate biomarker for active TB infection and 
for monitoring the results of TB treatment.6,16,17
In this cohort study, all possible infections 
and inflammation that could  increase the IP-
10 level and interfere the measurement result 
were excluded. Patient compliance was also 
an important factor that was considered in 
this study. Most of the subjects who met the 
inclusion and exclusion criteria to participate in 
this study suffered from MDR-TB. Nevertheless, 
no statistical difference in the level of IP-10 was 
seen  between sensitive and MDR-TB subjects. 
For that reason, analysis for MDR-TB and 
sensitive TB subjects was not differentiated. This 
feature is similar to the statement of Garcia et al. 
stating that the IP-10 level between sensitive and 
MDR-TB subjects is not different. The said study 
discovered that the IP-10 level decreases since 
the first week of TB treatment, which reflects 
the decrease of patient’s bacteriological load. An 
IP-10 reduction of >300 pg/mL in the first seven 
days of TB treatment is strongly associated 
with confirmed versus unconfirmed TB; thus, 
accordingly, the absence of these changes is 
predictive of unconfirmed TB.4
The result of this study is in line with the 
results in Hoel et al.18 that demonstrated an IP-
10 level before treatment of 1081pg/mL (886–
2321) and then decreases after 2 months TB 
treatment (p=0.012) down to 203 pg/mL (129–
427) (p=0.028) at the end of TB treatment.
Although this study did not seek to identify 
the cut-off for serum IP-10 level for the purpose 
of active pulmonary TB diagnosis, Hong et 
al.10 have suggested a cut off of >119.5 pg/mL. 
Among the subjects in this present study, 4 
subjects were  found to be negative in culture 
and smear microscopy tests, but positive in the 
Xpert MTB/RIF test. In this case, the IP-10 level 
can be considered as a sensitive non-sputum-
based marker to diagnose active pulmonary TB 
patients. 
This study has a limitation in terms of the lack 
of analysis of the correlation between decreased 
IP-10 level after 2 months of TB treatment and 
patient’s clinical conditions, laboratory results, 
and radiological findings.  
To conclude, The IP-10 level in active 
pulmonary TB patients decreases significantly 
(p<0.001) after 2 months of TB treatment both 
for sensitive and MDR-TB patients. Therefore, 
the IP-10 can be used as a non-sputum-based 
biomarker for TB treatment monitoring. Further 
studies are still needed to prove the correlation 
between the IP-10 level and patient’s clinical 
conditions, laboratory results, and radiological 
findings, as well as to explore the possibility 
of using the IP-10 as a new non-sputum-based 
biomarker for TB diagnostics.
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